Modified autologous T cells have been successfully used to treat tumors in a small proportion of patients. How can this general approach be used to treat more patients? A recent study of lymphoma, modeled in vitro, points to a potential approach.
Funding and Disclosures
Disclosure forms provided by the author are available with the full text of this article at NEJM.org.
This article was published on June 1, 2022, at NEJM.org.
Print Subscriber? Activate your online access.